Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside?
One year after the occurrence of the first case of infection by the Middle East Respiratory Syndrome coronavirus (MERS-CoV) there is no clear consensus on the best treatment to propose. The World Health Organization, as well as several other national agencies, are still working on different clinical...
Saved in:
Main Authors: | Emmanuel Faure, Julien Poissy, Anne Goffard, Clement Fournier, Eric Kipnis, Marie Titecat, Perinne Bortolotti, Laura Martinez, Sylvain Dubucquoi, Rodrigue Dessein, Philippe Gosset, Daniel Mathieu, Benoit Guery |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2014
|
Subjects: | |
Online Access: | https://doaj.org/article/be195de134d24f908da6e1ca896ecf3b |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lipid nanoparticles for targeted siRNA delivery – going from bench to bedside
by: Zatsepin TS, et al.
Published: (2016) -
Oncolytic Virotherapy: From Bench to Bedside
by: Ludi Yang, et al.
Published: (2021) -
Inflammation, Bone Healing and Osteonecrosis: From Bedside to Bench
by: Goodman SB, et al.
Published: (2020) -
Clinical utility of asthma biomarkers: from bench to bedside
by: Vijverberg SJH, et al.
Published: (2013) -
Antineutrophil cytoplasmic antibodies-associated glomerulonephritis: From bench to bedside
by: Yong-Xi Chen, et al.
Published: (2018)